Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license for the development and commercialization of cell therapies for cancer (85 FR 36872).… Continue Reading

KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading

KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading

KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology

On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” (84 FR 52890)by the National… Continue Reading